Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA2 | P47869 | 2/20 | 0.51 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.51 |
| ▸ | SLC2A2 | P11168 | 2/20 | 0.46 |
| ▸ | TSPO | P30536 | 2/20 | 0.44 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.43 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.43 |
| ▸ | ALB | P02768 | 1/20 | 0.43 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.43 |
| ▸ | DRD3 | P35462 | 1/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19730398 | 0.96 | GABRA2 (0.49) | GABRA2GABRB2SLC2A2TSPONR1I2 | |
| SCHEMBL19730391 | 0.87 | — | — | |
| SCHEMBL19730397 | 0.85 | SLC2A2 (0.55) | GABRA2GABRB2SLC2A2TSPONR1I2 | |
| SCHEMBL19730395 | 0.85 | GABRA2 (0.52) | GABRA2GABRB2SLC2A2 | |
| SCHEMBL19730396 | 0.85 | TSPO (0.50) | TSPO | |
| SCHEMBL19730390 | 0.78 | TSPO (0.47) | TSPO | |
| SCHEMBL1430336 | 0.77 | GABRA2 (0.63) | GABRA2GABRB2SLC2A2TSPONR1I2 | |
| SCHEMBL19738665 | 0.75 | SLC2A2 (0.51) | GABRA2GABRB2SLC2A2TSPONR1I2 | |
| SCHEMBL19730399 | 0.74 | TSPO (0.53) | TSPO | |
| SCHEMBL19730400 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10202376-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-02-12 | — | — | US | disclosed |
| US-20170362223-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-12-21 | — | — | US | disclosed |
| US-20170362223-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10202376-B2 | Heterocyclic compound | GRIN2A, GRIN1, GRIN2B | GABRA2 39/4885GABRB2 61/4885SLC2A2 4177/4885 |
| US-20170362223-A1 | HETEROCYCLIC COMPOUND | GRIN2A, GRIN1, GRIN2B | GABRA2 39/4885GABRB2 61/4885SLC2A2 4177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.